Heron Therapeutics Inc vs Williams Companies Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Williams Companies Inc trades at $72.43 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 1301× Heron Therapeutics Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Williams Companies Inc for 58 Days on average.
| HRTX | WMB | |
|---|---|---|
Market Cap | $68.01M | $88.48B |
Volume | 1,891,941 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $1.49 | $79.40 |
52-Week Low | $0.27 | $56.51 |
Typical Hold Time | 35 Days | 58 Days |
Enterprise Value | $174.75M | $119.11B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Williams Companies (WMB) trades at $71.46, down 1.28% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings show mixed results with Q1 2026 beat but Q4 2025 and Q2 2026 misses. The company benefits from stable fee-based revenues in the midstream energy sector, positioning it well for AI-driven natural gas demand growth.
WMB presents a compelling investment case with 79% analyst buy ratings and $87.27 consensus target, offering 22% upside potential. Key opportunities include dividend growth strategy and exposure to rising natural gas demand from data centers. Risks include energy market volatility, high debt levels at 52% debt-to-asset ratio, and execution challenges in capital-intensive projects. The stock's valuation at 28.47 P/E appears reasonable given growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →